http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pfizer (PFE), Merck (MRK) Treat First Patient in Avelumab Phase 3
-
Pfizer (PFE), Merck KGaA Treat First Patient in Avelumab Phase 3 in RCC Setting
-
Merck KGaA, Darmstadt, Germany, and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma
-
Merck and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma
-
Pfizer (PFE) Announces Tofacitinib Phase 3 Met Primary Efficacy Endpoints in Psoriatic Arthritis
-
Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis
-
Pfizer (PFE) Announces Bococizumab Phase 3 SPIRE-AI Met co-Primary Endpoints
-
Pfizer Announces Positive Topline Results from Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab
-
Pfizer (PFE), Allergan (AGN) Announce Receipt of FTC Request for Additional Info on Proposed Merger
-
Pfizer and Allergan Receive Request for Additional Information from Federal Trade Commission Regarding Proposed Combination
-
Pfizer (PFE), Bristol-Myers Squibb (BMY) Will Present 16 Abstracts at ACC.16
-
Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiology’s 65th Annual Scientific Session
-
Pfizer's (PFE) MAA for XELJANZ Accepted for Review by EMA
-
Pfizer Announces European Medicines Agency Accepted for Review Its Marketing Authorization Application for XELJANZ® (Tofacitinib Citrate) for the Treatment of Moderate to Severe Rheumatoid Arthritis
-
Pfizer Joins The Human Vaccines Project To Help Decode The Immune System
-
Pfizer's (PFE) Oral Tofacitinib Met Primary, Secondary Endpoints in Two Phase 3s
-
Pfizer Announces Oral Tofacitinib, an Investigational JAK Inhibitor, Meets Primary and Key Secondary Endpoints in Two Pivotal Phase 3 Ulcerative Colitis Trials
-
Pfizer (PFE) to Present New Data on Tofacitinib in UC and Crohn's Disease at ECCO
-
Pfizer to Present New Data on Investigational Tofacitinib in Inflammatory Bowel Disease at the 11th Congress of ECCO
-
Pfizer Celebrates a Year of Achievements in 2015 Annual Review
-
Pfizer (PFE) Announces XALKORI Approved by FDA for Treatment of Patients with ROS1-Positive Metastatic NSCLC
-
XALKORI® (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer
-
New Survey Reveals Many Living with Symptoms of Diabetic Nerve Pain Are Undiagnosed Despite Severe and Constant Pain
-
Pfizer (PFE) Enters $5 Billion Accelerated Stock Buyback
-
Pfizer Commences $5 Billion Accelerated Share Repurchase
-
Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
-
Pfizer (PFE), Merck KGaA, Verastem (VSTM) Collaborate to Evaluate Avelumab + VS-6063 Combo in Ovarian Cancer
-
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
-
Pfizer's (PFE) XELJANZ XR Extended-Release Tablets Approved by FDA
-
Pfizer Announces FDA Approval of XELJANZ® XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis
-
Pfizer (PFE) Reports Expanded FDA Approval For IBRANCE
-
Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer
-
Pfizer (PFE) Announces Wyeth Settlement Over Protonix-Related Rebating Claims
-
WYETH REACHES AGREEMENT IN PRINCIPLE TO RESOLVE MEDICAID DRUG REBATE CLAIMS FOR 2001-2006 PERIOD FOR PROTONIX
-
Pfizer Commends The FDA Advisory Committee’s Vote To Approve Proposed Biosimilar Infliximab, The First Biosimilar Monoclonal Antibody Reviewed, For All Eligible Indications
-
Portola Pharma (PTLA) Enters Licensing Agreements for Investigational Agent Andexanet in Japan (BMY) (PFE)
-
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
-
Pfizer (PFE) Acquires Treerly Health from Sino Pharma
-
Pfizer Acquires Treerly and Its Family of Products from Sirio Pharma
-
Pfizer (PFE) to Include Early-Stage Scientific Innovations in R&D Equity Investment Strategy
-
Pfizer Expands R&D Equity Investment Strategy to Access Early-Stage Scientific Innovations
-
FuelCell Energy (FCEL) Plans 5.6MW Fuel Cell System for Pfizer (PFE)
-
Pfizer's (PFE) Phase 3 Study of Pristiq in MDD Misses Primary Endpoint
-
Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder
-
ViiV Healthcare to Acquire Bristol-Myers Squibb's (BMY) Investigational HIV Medicines Pipeline
-
Pre-Open Stock Movers 12/15: (KTOV) (LL) (VRX) Higher; (NEOT) (KMT) (ZOES) Lower (more...)
-
Pfizer Declares First-Quarter 2016 Dividend
-
Bristol-Myers Squibb (BMY) , Pfizer (PFE) Announce Encouraging Post-Hoc Data from Phase 3 AMPLIFY in VTE
-
AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with
-
PureTech Names Scientific Advisory Board and Expands Senior Team

